PACE-AMR

Pathways to Antimicrobial Clinical Effectiveness. Accelerating and enhancing the preclinical AMR pipeline.

Clive Mason

Programme Director

4 past transactions

Oxford Drug Design

Grant in 2025
Oxford Drug Design focuses on developing innovative therapies to combat drug-resistant infections through advanced drug discovery techniques. The company employs a multidisciplinary research approach that integrates computational chemistry, cheminformatics, mathematics, and cloud computing to enhance the drug discovery process. Its flagship platform, DrugFinder, utilizes cutting-edge technologies to facilitate computer-aided drug discovery, covering all stages from target identification to preclinical studies. By addressing high unmet medical needs, Oxford Drug Design aims to provide healthcare professionals with effective new antibiotics for treating challenging diseases, including cancer and other conditions associated with drug resistance.

Infex Therapeutics

Grant in 2025
Infex Therapeutics acquire, develop and license drugs to treat pandemic infections.

Centauri Therapeutics

Grant in 2024
Centauri Therapeutics is a biotechnology company focused on the discovery and development of innovative immunotherapeutics aimed at addressing life-threatening diseases. Utilizing its proprietary Alphamer technology, Centauri creates chemically synthesized molecules that redirect naturally occurring antibodies to specific pathogens, enhancing the body's immune response. The company's dual-action approach involves directly targeting cell surface antigens while employing a glycan effector domain to stimulate a robust polyclonal immune response. This mechanism promotes cell death via enhanced complement fixation, antibody-dependent cellular cytotoxicity, and phagocytosis by myeloid cells. Centauri has demonstrated strong pre-clinical results, showcasing significant improvements in complement fixation and opsonophagocytosis for both anti-bacterial and oncology therapeutics, as well as in vivo proof-of-concept data across various infection models.

Glox Therapeutics

Grant in 2024
Glox Therapeutics specializes in developing precision antibiotic therapies derived from naturally occurring bacteriocins. Their focus is on targeting and eliminating specific, hard-to-treat gram-negative bacterial pathogens that are resistant to traditional antibiotics. By preserving the patient's microbiome, their approach aims to minimize side effects and provide a more balanced treatment strategy, thereby advancing the field of antimicrobial therapy.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.